Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2024 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Cancer Discov. 2024 Jan 12;14(1):66-75. doi: 10.1158/2159-8290.CD-23-0670.
Cancer Discov. 2024.
PMID: 37930156
Clinical Trial.
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, Eathiraj S, Sampath D, Rogers KA, Byrd JC, Woyach JA.
Muhowski EM, et al.
J Hematol Oncol. 2022 Nov 15;15(1):166. doi: 10.1186/s13045-022-01386-1.
J Hematol Oncol. 2022.
PMID: 36380319
Free PMC article.
Item in Clipboard
Development and validation of a GC method for a key nemtabrutinib intermediate: Implementation of an in-situ free base sample preparation protocol.
Rivera NR, Zewge D, Arvary R, Lin M, Lohani S.
Rivera NR, et al.
J Pharm Biomed Anal. 2024 Apr 15;241:116002. doi: 10.1016/j.jpba.2024.116002. Epub 2024 Feb 1.
J Pharm Biomed Anal. 2024.
PMID: 38309100
Item in Clipboard
Cite
Cite